-
Something wrong with this record ?
Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties
E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Aldehydes chemistry pharmacology toxicity MeSH
- Antioxidants chemistry pharmacology MeSH
- Cell Line MeSH
- Iron Chelating Agents chemistry pharmacology MeSH
- Hydrazones chemistry pharmacology toxicity MeSH
- Humans MeSH
- MCF-7 Cells MeSH
- Myoblasts drug effects MeSH
- Oxidative Stress drug effects MeSH
- Hydrogen Peroxide toxicity MeSH
- Antineoplastic Agents chemistry toxicity MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010697
- 003
- CZ-PrNML
- 005
- 20170426102624.0
- 007
- ta
- 008
- 160408s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0112059 $2 doi
- 024 7_
- $a 10.1371/journal.pone.0112059 $2 doi
- 035 __
- $a (PubMed)25393531
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Potůčková, Eliška $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic. $7 xx0153394
- 245 10
- $a Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties / $c E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,
- 520 9_
- $a Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.
- 650 _2
- $a aldehydy $x chemie $x farmakologie $x toxicita $7 D000447
- 650 _2
- $a protinádorové látky $x chemie $x toxicita $7 D000970
- 650 _2
- $a antioxidancia $x chemie $x farmakologie $7 D000975
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrazony $x chemie $x farmakologie $x toxicita $7 D006835
- 650 _2
- $a peroxid vodíku $x toxicita $7 D006861
- 650 _2
- $a chelátory železa $x chemie $x farmakologie $7 D007502
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a myoblasty $x účinky léků $7 D032446
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hrušková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Bureš, Jan $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Kovaříková, Petra $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Špirková, Iva A $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Pravdíková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Kolbabová, Lucie $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Hergeselová, Tereza $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Hašková, Pavlína $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Jansová, Hana $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Macháček, Miloslav $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Jirkovská, Anna $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Richardson, Vera $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Lane, Darius J R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Kalinowski, Danuta S $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Richardson, Des R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Vávrová, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Šimůnek, Tomáš $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e112059
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25393531 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20170426102943 $b ABA008
- 999 __
- $a ok $b bmc $g 1114126 $s 935065
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 11 $d e112059 $e 20141113 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20160408